Bennett Lawrence Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bennett Lawrence Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-1,088,815	Closed	-$17.2M	–	101
2014 Q2	$17.2M	Buy	1,088,815 +842,400	+342%	+$12M	3.03%	5
2014 Q1	$3.73M	Buy	+246,415	New	+$2.78M	0.55%	56

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

MRM

Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bennett Lawrence Management's HZNP Position: Q3 2014 in Review

Bennett Lawrence Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2014, closing a stake of 1,088,815 shares — an estimated $17.2M sold.

Bennett Lawrence Management first reported a position in HZNP in Q1 2014 and held it in 2 quarters. The position peaked at $17.2M in Q2 2014. 120 funds tracked by Wall St. Rank hold HZNP as of Q3 2014.

Bennett Lawrence Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2014 after selling out during the quarter.
Bennett Lawrence Management sold 1,088,815 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2014, an estimated $17.2M.
Bennett Lawrence Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 2 quarters.
Bennett Lawrence Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $17.2M in Q2 2014.
120 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2014.

Based on Bennett Lawrence Management's 13F filing for Q3 2014, filed 28 Oct 2014.